Type: Keyphrase
Name: Exon
First reported Apr 21 2014 - Updated Apr 22 2014 - 4 reports

Sarepta Therapeutics CEO Discusses Q1 2014 Results - Earnings Call Transcript

Sarepta Therapeutics, Inc. ( SRPT ) Q1 2014 Earnings Conference Call April 18, 2014 8:00 AM ETOperatorWelcome to the Sarepta Therapeutics Incorporated to give regulatory update Conference Call. My name is Paulette and I will be your operator for today’s ... [Published Seeking Alpha - Apr 21 2014]
First reported Apr 22 2014 - Updated Apr 22 2014 - 1 reports

RCAN1 Overexpression Exacerbates Calcium Overloading-Induced Neuronal Apoptosis

Down Syndrome (DS) patients develop characteristic Alzheimer's Disease (AD) neuropathology after their middle age. Prominent neuronal loss has been observed in the cortical regions of AD brains. However, the underlying mechanism leading to this neuronal ... [Published PLoS medicine - Apr 22 2014]
Entities: Exon, Calcium, A23187
First reported Apr 21 2014 - Updated Apr 21 2014 - 1 reports

Molecular Characterization and Expression Analysis of Chloroplast Protein Import Components in Tomato (Solanum lycopersicum)

The translocon at the outer envelope membrane of chloroplasts (Toc) mediates the recognition and initial import into the organelle of thousands of nucleus-encoded proteins. These proteins are translated in the cytosol as precursor proteins with cleavable ... [Published PLoS medicine - Apr 21 2014]
First reported Apr 21 2014 - Updated Apr 21 2014 - 1 reports

Sector Update: Health Care

Eteplirsen is Sarepta's lead exon-skipping drug candidate in development for the treatment of patients with DMD who have a genotype amenable to skipping of exon 51.SRPT recently changed hands at $43.58, in a 52-week range of $12.12 to $56.61.Theravance ... [Published Nasdaq - Apr 21 2014]
First reported Apr 21 2014 - Updated Apr 21 2014 - 1 reports

USeq 8.7.9 (BSD License)

USeq is designed to be a collection of software tools for both low and high level analysis of next generation, ultra high throughput signature sequencing data.You can now use this Java-based utility to quickly analyze next generation sequencing data from ... [Published Softpedia - Apr 21 2014]
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

Findings from University of Navarra Reveals New Findings on Lung Cancer

(NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Research findings on Oncology are discussed in a new report. According to news reporting from San Sebastian, Spain, by NewsRx journalists, research stated, "Abnormal alternative splicing ... [Published NewsRX - Apr 18 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Joint resigns BHS account

, and went on to create the fashion retailers' autumn collection campaign.The Joint founders Damon Collins and Richard Exon said: "We've loved our time working with BHS, and are proud of the work that we produced together."However, with wholesale personnel ... [Published Brand Republic - Apr 17 2014]
Entities: Resignation, Exon, Retailer
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

HIV-1 Tat second exon limits the extent of Tat-mediated modulation of interferon-stimulated genes ...

We have shown that HIV-1 Tat interaction with MAP2K3, MAP2K6, and IRF7 promoters is key to IFN-stimulated genes activation in immature dendritic cells and macrophages.Results: We evaluated how Tat alleles and mutants differ in cellular gene modulation ... [Published 7thSpace - Apr 17 2014]
Entities: Exon, Mutant, macrophage
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Patent Application Titled "Stromal Antigen 2 (Stag2) Compositions and Methods" Published Online

By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- According to news reporting originating from Washington, D.C. , by NewsRx journalists, a patent application by the inventors SOLOMON, David ( San Francisco, CA ); Kim, Jung-Sik ( Clarksburg, ... [Published HispanicBusiness.com - Apr 16 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Pinch Brings Chinese Dumplings to Farmers’ Markets With Plans for a Restaurant

D.C.’s farmers' markets are increasingly selling much more than fruits and vegetables, with an array of prepared foods from wood-fired pizzas to vegetarian tacos. The latest must-try at the market? Chinese dumplings from Pinch.Pinch was started by attorney ... [Published Washington City Paper - Apr 16 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Joint venture between US and Iraqi operators to run refinery in Iraq’s Kurdistan region

The refinery near the Kurdish capital Erbil will be operated by the private Kurdish group Rezhwan Co., which will process the crude from purchasing above ground reserves in Taq Taq.Black Diamond investment partners will keep 70.5 per cent of the gross ... [Published Oil & Gas Technology - Apr 16 2014]
First reported Apr 07 2014 - Updated Apr 07 2014 - 2 reports

Malaysia Airlines MH370: Better ocean maps could aid search, expert says (ABC)

Better ocean maps would assist in the search for missing Malaysia Airlines flight MH370, an expert says.Australia has the third-largest marine exclusive economic zone in the world, but the CSIRO estimates only about 12 per cent of it has been mapped.Australian ... [Published Yahoo! News Australia - Apr 07 2014]


"The mechanism we discovered explains how cancer cells eliminate the anticancer form of Mnk2 without changing their DNA, and how they become resistant to anticancer treatments—a problem which exists for almost every cancer treatment today" said senior author Dr. Rotem Karni, senior lecturer of biochemistry and molecular biology at the Hebrew University of Jerusalem
Chris Garabedian, president and chief executive officer says, "As we announce our plan to submit an eteplirsen NDA by the end of 2014, we are very pleased with the detailed guidance that the FDA has provided us on a potential eteplirsen approval pathway and their support of a historically controlled eteplirsen confirmatory study. We also appreciate that the FDA shares our urgency in dosing a broader base of eteplirsen patients and has encouraged us to begin the clinical program with our follow-on exon-skipping drugs as soon as possible." [Related -]As such, management plans to initiate several additional clinical studies with eteplirsen later this year in exon-51 amenable genotypes
...With regards to a NDA for eteplirsen, the FDA stated that "with additional data to support the efficacy and safety of eteplirsen for the treatment of DMD, an NDA should be fillable" . In a moment, we will talk about the types of additional efficacy and safety data that we will be generating and compiling in the remainder of the year...
"Today signifies yet another historic moment for CASIS and our launch partner, SpaceX," said President and Executive Director Gregory H Johnson. "The research that is now on the ISS has the potential to unlock secrets that could create therapies to improve human health and performance. Additionally, this launch culminates our first official increment period of Advancing Research Knowledge 1. This initial launch period has been instrumental in the further development of CASIS and we look forward to sending additional exciting and innovative research capable of enhancing science in space, for life on Earth."

More Content

All (275) | News (244) | Reports (0) | Blogs (30) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
Severe hypoxia exerts parallel and cell-specifi... [Published BMC - 53 mins ago]
The Association of 5-HT2A, 5-HTT, and LEPR Poly... [Published PLoS medicine - 16 hours ago]
Tripartite Motif-Containing Protein 30 Modulate... [Published PLoS medicine - 19 hours ago]
Sarepta Therapeutics To File NDA For Muscular D... [Published Bioresearch Online - 20 hours ago]
Kallikrein 3 and vitamin D receptor polymorphis... [Published 7thSpace - 23 hours ago]
US stock market daily report (April 21, 2014, M... [Published Stock Markets Review - Apr 22 2014]
US FDA clears pathway for Sarepta’s eteplirsen ... [Published Pharma Letter - Apr 22 2014]
Mannose Binding Lectin and Susceptibility to Rh... [Published PLoS medicine - Apr 22 2014]
Expression of Caveolin 1 Is Enhanced by DNA Dem... [Published PLoS medicine - Apr 22 2014]
RCAN1 Overexpression Exacerbates Calcium Overlo... [Published PLoS medicine - Apr 22 2014]
A new Adamts9 conditional mouse allele identifi... [Published Bionity.com - Apr 22 2014]
An etiologic regulatory mutation in IRF6 with l... [Published Bionity.com - Apr 22 2014]
Genetic Analysis of Genes Related to Tight Junc... [Published PLoS medicine - Apr 22 2014]
A Pair of Gene Splice Isoforms Has Opposite Eff... [Published Biotech Daily - Apr 22 2014]
Sarepta Therapeutics Inc. (SRPT): $54 Approved ... [Published I Stock Analyst - Apr 21 2014]
Dbx1 Is a Direct Target of SOX3 in the Spinal Cord [Published PLoS medicine - Apr 21 2014]
High-Affinity Glucose Transport in Aspergillus ... [Published PLoS medicine - Apr 21 2014]
Molecular Characterization and Expression Analy... [Published PLoS medicine - Apr 21 2014]
FDA Guides Sarepta on Muscular Dystrophy Drug NDA [Published Drug Discovery and Development - Apr 21 2014]
Sarepta Therapeutics CEO Discusses Q1 2014 Resu... [Published Seeking Alpha - Apr 21 2014]
New Trials Will Assess Muscle Disorder Drug Aft... [Published PT Community - Apr 21 2014]
FDA regulators offer makers of eteplirsen a pat... [Published Pittsburgh Post-Gazette - Apr 21 2014]
Sarepta Therapeutics Inc (SRPT) Soaring On FDA ... [Published Value Walk - Apr 21 2014]
The FDA Gives Sarepta Therapeutics Inc. a Way F... [Published Motley Fool - Apr 21 2014]
CASIS Payloads Berthed With the International S... [Published Individual.com - Apr 21 2014]
Sarepta to Resubmit Application for Duchenne Dr... [Published Xconomy - Apr 21 2014]
Sarepta Therapeutics jumps on plans to submit n... [Published Proactive Investors USA - Apr 21 2014]
Sector Update: Health Care [Published Nasdaq - Apr 21 2014]
Sarepta Therapeutics Inc announces plans to sub... [Published Reuters - Apr 21 2014]
Sector Update: Health-Care Shares Flat Pre-Mark... [Published Nasdaq - Apr 21 2014]
1 2 3 4 5 6 7 8 9 10
In Focus
Content Volume
Document Volume


sort by: Date | Relevance
Terry Gaasterland to Speak at Bioinformatics Co... [Published PR.com Press Releases - Apr 19 2014]
San Diego, CA, April 19, 2014 --( PR.com )-- Terry Gaasterland, Professor of Computational Biology and Genomics at University of California, San Diego will give a presentation on “Integrating exome sequencing, mRNA-seq, and microRNA-seq to identify ...
Should You Buy Stratasys? [Published Wall St. Cheat Sheet - Apr 08 2014]
Source: Thinkstock Shares of additive manufacturing technology companies (or, 3D printing companies) have been weak so far in 2014. Investors were irrationally exuberant when it came to the future prospects of these companies. While they are correct ...
Evolutionary dynamics and tissue specificity of... [Published Genome Research current issue - Apr 01 2014]
Long intergenic noncoding RNAs (lincRNAs) play diverse regulatory roles in human development and disease, but little is known about their evolutionary history and constraint. Here, we characterize human lincRNA expression patterns in nine tissues across ...
[tt] [GRG] Non-coding DNA may have applicabilit... [Published TranshumanTech - Apr 01 2014]
http://www.eurekalert.org/pub_releases/2014-03/asop-nff033114.php New functions for 'junk' DNA? Non-coding DNA sequences found in all plants may have undiscovered roles in basic plant development and response to the environment IMAGE: This image shows ...
'Junk' DNA - Now With Even More Functions! [Published Scientific Blogging - Mar 31 2014]
DNA is the molecule that encodes the genetic instructions enabling a cell to produce the thousands of proteins it typically needs. The linear sequence of the A, T, C, and G bases in what is called coding DNA determines the particular protein that a short ...
1 2 3 4 5 6

Press Releases

sort by: Date | Relevance
Parent Project Muscular Dystrophy to Fund $1 Mi... [Published PR Newswire - Aug 14 2013]
Contact Us

Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.